Low Density Lipoprotein (LDL) News and Research

RSS

Cholesterol-lowering drugs could be alternative treatment for people who take statins

A new class of cholesterol-lowering drugs that target a recently discovered regulator of harmful cholesterol could be an alternative or complementary treatment for the 30 million people who take statins, after the first trial in humans confirms the technique’s feasibility and safety.

4 Oct 2013

Statin medications pose no threat to short-term memory and may protect against dementia

A review of dozens of studies on the use of statin medications to prevent heart attacks shows that the commonly prescribed drugs pose no threat to short-term memory, and that they may even protect against dementia when taken for more than one year.

2 Oct 2013

Preoperative statin therapy improves results for isolated CABG and AVR operations

Patients receiving statin therapy before coronary artery bypass grafting (CABG) surgery appear to have a reduced risk of post-surgical mortality, stroke, and atrial fibrillation (irregular or rapid heart rate), according to an article in the October 2013 issue of The Annals of Thoracic Surgery.

1 Oct 2013

Research shows commonly prescribed statin medicines can adversely affect cognitive function

New research that looked at whether two commonly prescribed statin medicines, used to lower low-density lipoprotein (LDL) or 'bad cholesterol' levels in the blood, can adversely affect cognitive function has found that one of the drugs tested caused memory impairment in rats.

26 Sep 2013

Researchers reveals key role for stem cells that promote inflammation in atherosclerosis

University at Buffalo translational researchers are developing a richer understanding of atherosclerosis in humans, revealing a key role for stem cells that promote inflammation.

24 Sep 2013

Expert offers tips to help college students avoid serious health conditions down the road

To attract customers, restaurant chains have been rolling out budget deals, offering $5 pizzas, $3 meals — even $1 sandwiches. But while these new offerings are light on its customers' wallets, they hit them where it hurts in terms of calories, fat, and sodium content.

17 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Study: Fixed-dose combination medication helps CVD patients

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Reimbursement systems appear to impact on achievement of cholesterol lowering targets

Dr Gitt said: "There are wide variations between European countries in the achievement of LDL-cholesterol (LDL-C) targets. However the effect of different reimbursement systems on meeting the targets was unknown."

2 Sep 2013

CAD patients with very low LDL-C levels benefit from statin treatment

Dr Nakano said: "Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with CAD and high LDL-C levels.1,2 But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL-C levels."

2 Sep 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

New CardioChek Plus analyzer delivers rapid test results for lipids and glucose

Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer of the CardioChek family of point-of-care diagnostic products, introduced the CardioChek Plus analyzer today at the annual American Association for Clinical Chemistry (AACC) in Houston.

30 Jul 2013

Study: Heart disease emerges as number one killer among Indians

Heart disease has emerged as the number one killer among Indians, according to a recent study by the Registrar General of India ( RGI) and the Indian Council of Medical Research (ICMR).

25 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Pharmaceutical companies race for new cholesterol drugs, Roche abandons diabetes drug development

A discovery of a rare mutation that affects cholesterol has ignited hopes of a prescription that can help prevent heart attacks. In the meantime, the announcement by Roche could pose more questions about controversial diabetes medicines. Also a federal report warns Americans of using some Internet pharmacies.

11 Jul 2013

First Edition: July 10, 2013

Today's early morning highlights from the major news organizations, including articles about House Republican plans to seek a delay in the health law's requirement that nearly all Americans get health insurance.

10 Jul 2013

Activation of brown fat increases heart-related mortality during winter

More people die from heart-disease during the winter months, and according to a new study published in the journal Cell Metabolism, the increase in mortality is possibly due to the accelerated growth of atherosclerotic plaque in the blood vessels caused by the activation of brown fat by the cold.

3 Jul 2013

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

3 Jul 2013

Low Density Lipoprotein (LDL) News and Research

Cholesterol-lowering drugs could be alternative treatment for people who take statins

Statin medications pose no threat to short-term memory and may protect against dementia

Preoperative statin therapy improves results for isolated CABG and AVR operations

Research shows commonly prescribed statin medicines can adversely affect cognitive function

Researchers reveals key role for stem cells that promote inflammation in atherosclerosis

Expert offers tips to help college students avoid serious health conditions down the road

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Study: Fixed-dose combination medication helps CVD patients

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Reimbursement systems appear to impact on achievement of cholesterol lowering targets

CAD patients with very low LDL-C levels benefit from statin treatment

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

New CardioChek Plus analyzer delivers rapid test results for lipids and glucose

Study: Heart disease emerges as number one killer among Indians

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Pharmaceutical companies race for new cholesterol drugs, Roche abandons diabetes drug development

First Edition: July 10, 2013

Activation of brown fat increases heart-related mortality during winter

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News